Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Recce Pharmaceuticals.
RELATED STOCKHEAD STORIES
Health & Biotech
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners
News
Things you may not know about Made in Australia, and ASX stocks that manufacture right here
Health & Biotech
ASX Health Winners March: A rebound? Aussie biotech sector is on the radar of Asian investors
Health & Biotech
ASX Health Stocks: Acrux jumps 70pc after launching its acne gel in the US
News
ASX Large Caps: Coles takes lead as iron ore miners struggle; Bitcoin nears US$56k
Health & Biotech
ASX Health Stocks: Recce, Cynata say their diabetic foot ulcer trials are going great guns
Health & Biotech
ASX Health Stocks: Amplia gets FDA green light to commence trial; Recce study meets all primary endpoints
Health & Biotech
ASX Health Stocks: More positive data for Recce’s drug, Cynata expects trial results in Q1
Health & Biotech
ASX Health Stocks: Chimeric jumps 35pc as cell therapy drug shows pre-clinical efficacy
Health & Biotech
ASX Health Stocks: Recce moves forward in Phase 1/2 study; EMV unveils Gen 2 helmet scanner for ambulance
News
Rise and Shine: Everything you need to know before the ASX opens
News
ASX Health Stocks: Bod Science surges 20pc on cannabis trial results; Recce gets Vietnam trade mark
Health & Biotech
ASX Health Stocks: Recce Pharma jumps 20pc after saying its gel could heal antibiotic-resistant infections
News
Top 10 at 10: James Hardie delivers super strong quarter; Auris digs up more gold
News
In Case You Missed It: Gold, biotech and some gas
Health & Biotech
ASX Health Stocks: Recce Pharma and Impedimed surge 15pc after positive announcements
News